Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Bladder Cancer Oncogenome Project

Funder: American Association For Cancer Research

Funding period
USD 252 K
Funding amount
Abstract
Bladder cancer is a common malignancy with an estimated 67,000 new cases in the United States for the year 2007. It is a devastating illness requiring frequent medical care and follow-up for patients with early stage disease and few effective therapies for patients with advanced disease. Novel therapies and tools to predict outcome are desperately needed. Over the past several years, there has been a major paradigm shift in cancer research with development of novel “targeted” agents that are designed to attack unique molecular alterations within cancer cells. Although these targeted agents have shown much promise, ongoing research is also directed at developing patient-specific therapies by learning more about the molecular features of a tumor within an individual patient. Unlike normal cells, cancer cells are characterized by alterations in their molecular machinery related to damage or changes to their DNA called mutations. These mutations can lead to uncontrolled cell growth, an inability to undergo normal cell death, and a propensity for cancerous cells to travel to other sites in the body referred to as metastases. Several commonly mutated genes in bladder cancer include HRAS, FGFR3, PIK3CA, CDKN2A, RB1, and TP53 as well as others. The objective of the current proposal is to characterize known common mutations and define rare and new mutations in bladder tumors using a Sequenom assay that utilizes a technology called matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) with the ultimate goal to develop individualized treatment strategies for patients with bladder cancer. This technology has several advantages over standard mutation detection methods including excellent accuracy, the ability to rapidly analyze a tumor specimen for multiple mutations simultaneously and lower cost. Unlike other cancers where invasive biopsies need to be performed to access tumor tissue, patients with bladder cancer routinely undergo non-invasive biopsies using a device inserted into the urethra to evaluate the inside of the bladder, and urine collection for the detection of cancerous cells under the microscope, thus making bladder cancer an excellent disease model for further development of the MALDI-TOF MS technology. The proposal first seeks to determine the type and frequency of mutations that are present in a series of early stage and later stage bladder cancer tissue specimens. Second, we will correlate the presence or absence of various mutations with outcome; and finally, we will evaluate the use of novel therapies that target particular mutations in patients with advanced bladder cancer. This work will provide the foundation for clinical trials designed to evaluate novel targeted agents in patients who are most likely to respond and thereby accelerate the development of promising therapies.
Similar projects All >
Sorted by: Start Date
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021

System

Categories
  • FOR (ANZSRC)

    0601 Biochemistry and Cell Biology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Genetics

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science